Moving Beyond Daily Medication: How Long-Acting Formulations Are Improving Quality of Life for Patients with Chronic Diseases

By:DengYue International Business Division

For many years, drug development focused primarily on two objectives: identifying new therapeutic targets and improving treatment efficacy. Increasingly, however, another issue has gained attention in real-world disease management: even when a therapy is effective, can patients continue treatment over the long term?

This question becomes especially important in diseases that require long-term management.

Patients with diabetes may miss injections because of work schedules. Patients with psychiatric disorders may discontinue medication after symptom improvement. Individuals living with HIV may develop treatment fatigue after years of daily medication. Cancer patients often face maintenance treatment that extends for months or even years. In many cases, treatment failure is not necessarily driven by drug inefficacy, but by difficulties maintaining the intended treatment pathway over time.

As a result, the pharmaceutical industry has gradually shifted its attention from simply asking, “How can drugs become more effective?” to a broader question:

“How can treatment become easier to maintain?”

The rapid development of long-acting formulations has emerged within this context. By modifying drug delivery mechanisms, extending therapeutic duration, and reducing dosing frequency, long-acting technol ogies are reshaping the management of chronic diseases.

As a platform focused on global innovative medicines and developments in Chinese pharmaceutical research, DengYueMed continuously follows advancements in long-acting formulations, drug delivery systems, and emerging therapeutic technologies, helping international patients better understand evolving treatment landscapes.

From Drug Efficacy to Treatment Adherence: Why Adherence Matters More Than Ever

In clinical trials, patients are closely monitored through scheduled visits, reminders, and structured follow-up programs. Under these controlled conditions, treatment outcomes can often be optimized. Real-world practice, however, presents a very different environment.

Long-term studies suggest that treatment adherence among patients with chronic diseases may remain at only 40–60% in some settings. Multiple factors can contribute to declining adherence:

● Forgetting medication or injections

● Long-term treatment fatigue

● Concerns about adverse effects

● Conflicts with work or daily routines

● The burden of frequent hospital visits

● Psychological stress associated with chronic illness

These factors may appear minor individually, but their cumulative impact often becomes increasingly significant over time.

For example, some patients with hypertension reduce medication after symptom improvement; in psychiatric disorders, discontinuation may increase the risk of relapse; and in antiviral therapy, inconsistent treatment can compromise long-term disease control.

The fundamental goal of long-acting formulations is to reduce the burden of maintaining treatment over time.

What Are Long-Acting Formulations?

Long-acting formulations generally refer to pharmaceutical products designed using Drug Delivery Systems (DDS) that enable medications to remain active in the body for extended periods through controlled release mechanisms.

Common goals include:

● Extending drug half-life

● Reducing dosing frequency

● Minimizing fluctuations in drug concentration

● Maintaining stable drug exposure

● Improving patient adherence

The key distinction from conventional formulations often lies not in the drug molecule itself, but in how the therapy enters and behaves within the body.

Traditional treatment patterns often follow:

Daily dosing → Rapid increase in drug concentration → Decline in concentration → Repeated administration

Long-acting approaches aim for:

Controlled release → Stable maintenance → Prolonged therapeutic activity

This helps reduce peak-trough fluctuations and may improve long-term treatment experience.

GLP-1 Therapies: How Long-Acting Approaches Are Reshaping Metabolic Disease Management

Among recent developments, GLP-1 receptor agonists may represent one of the most visible examples of successful long-acting therapy.

Earlier GLP-1 products often required daily administration, such as liraglutide. Advances in molecular engineering and formulation technologies have enabled newer therapies to transition toward weekly dosing schedules.

Representative products include:

● Ozempic (semaglutide)

● Wegovy (semaglutide)

● Mounjaro (tirzepatide)

● Trulicity (dulaglutide)

The significance of these therapies extends beyond reducing injection frequency.

Longer duration of action may contribute to more stable drug exposure and potentially reduce fluctuations in glucose control while simplifying long-term disease management.

At the same time, GLP-1 therapies have expanded beyond diabetes and are increasingly being investigated or used in:

● Obesity management

● Cardiovascular risk reduction

● Chronic kidney disease

● Metabolic dysfunction-associated steatohepatitis (MASH)

Long-acting technologies are therefore influencing not only treatment schedules but also broader approaches to disease management.

Psychiatric Disorders: Breaking the Cycle of Discontinuation and Relapse

One of the major challenges in psychiatric care is maintaining long-term treatment continuity.

Patients may discontinue medication after symptom improvement, forget daily doses, or develop resistance toward long-term treatment routines. These issues can increase the likelihood of relapse.

As a result, Long-Acting Injectable Antipsychotics (LAIs) have seen substantial growth.

Representative therapies include:

● Invega Sustenna (monthly)

● Invega Trinza (every three months)

● Invega Hafyera (every six months)

● Abilify Maintena

● Aristada

The value of long-acting injections extends beyond convenience. Their importance lies in maintaining continuity of care and potentially reducing relapse and hospitalization rates.

HIV Treatment: Moving Beyond Daily Medication

Long-term HIV management depends heavily on consistent treatment adherence.

Traditional antiretroviral therapies generally require daily administration, and over time some patients may experience treatment fatigue.

Long-acting antiviral therapies are now changing this landscape.

Representative therapies include:

● Cabenuva

● Sunlenca (lenacapavir)

Some treatment approaches now allow administration every two months or even every six months.

For many patients, reducing medication frequency may alleviate not only practical treatment burdens but also some of the psychological stress associated with daily disease reminders.

Oncology Is Also Entering the Long-Acting Era

Cancer treatment continues to rely heavily on scheduled administration cycles.

In immunotherapy, for example, many PD-1/PD-L1 therapies currently require intravenous administration every two to four weeks.

Representative therapies include:

● Keytruda

● Opdivo

● Tecentriq

● Tislelizumab

● Toripalimab

Several emerging development strategies are now being explored:

● Subcutaneous (SC) formulations

● Fc half-life extension technologies

● Microsphere-based sustained-release systems

● Implantable drug delivery platforms

The goal is not necessarily to alter therapeutic mechanisms but to reduce treatment burden while maintaining efficacy.

For patients requiring long-term maintenance therapy, extended dosing intervals could eventually mean fewer hospital visits and greater flexibility in daily life.

Drug Delivery Systems Are Becoming a Major Competitive Area

The evolution of long-acting therapies depends not only on drug molecules but also on advances in delivery technologies.

Current approaches include:

Microsphere Technology

Drugs are encapsulated within biodegradable materials that gradually release medication over time.

Common applications include:

● Long-acting hormone therapies

● Long-acting psychiatric medications

PEGylation Technology

Attachment of polyethylene glycol structures can reduce drug clearance and prolong circulation time.

Fc Fusion Technology

Modification using antibody Fc structures can extend half-life.

Applications include:

● Long-acting antibodies

● Protein-based therapies

Emerging Delivery Platforms

Examples include:

● Nanoparticle carriers

● Hydrogel systems

● In situ implant technologies

Future delivery systems may move beyond simply prolonging duration and toward more adaptive or responsive drug release mechanisms.

China's Long-Acting Drug Development Is Accelerating

Historically, long-acting formulations were largely dominated by multinational pharmaceutical companies. In recent years, however, Chinese companies have significantly expanded their presence in this field.

Areas of active development include:

● Long-acting GLP-1 therapies

● Long-acting growth hormones

● Long-acting antibodies

● Microsphere technology platforms

● Long-acting nucleic acid therapeutics

● Long-acting PD-1 programs

As innovation capabilities continue to expand, Chinese pharmaceutical companies are gradually moving beyond formulation optimization toward original platform technologies.

Future competition may increasingly depend on integrated capabilities combining:

Drug molecule + delivery technology + long-acting platform development

Conclusion

Long-acting formulations have not changed the fundamental purpose of medical treatment, but they are changing the relationship between patients and therapy.

Historically, treatment often required patients to adapt to medications. Increasingly, new technologies are attempting to adapt treatments to patients’ lives.

From GLP-1 therapies to HIV management, and from psychiatric care to oncology, long-acting approaches are no longer limited to a single therapeutic area. They are becoming an increasingly important direction in global disease management.

DengYue continues to follow global developments in long-acting formulations, innovative drug delivery technologies, and emerging pharmaceutical research trends, providing international patients and industry partners with information support and healthcare resource connections.

This article is intended for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Treatment decisions should always be made in consultation with qualified healthcare professionals.